INSULET CORP
About INSULET CORP
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $2.7B
- Net income
- $247.1M
- Total assets
- $3.2B
- Market cap
- $10.6B
- Gross margin
- 71.6%
- Operating margin
- 17.5%
- Net margin
- 9.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.7B
- Cost of revenue
- $768.2M
- Gross profit
- $1.9B
- Operating expenses
- $1.5B
- Operating income
- $473.8M
- Income tax
- $92.4M
- Net income
- $247.1M
- EPS (basic)
- $3.51
- EPS (diluted)
- $3.48
Balance sheet
- Total assets
- $3.2B
- Current assets
- $1.9B
- Total liabilities
- $1.7B
- Current liabilities
- $680.1M
- Shareholders’ equity
- $1.5B
Cash flow
- Operating cash flow
- $569.3M
- Investing cash flow
- -$222.7M
- Financing cash flow
- -$595.3M
- Net cash flow
- -$237.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $10.6B
- P/E ratio
- 43.5
- EPS (diluted)
- $3.48
- Shares outstanding
- 70.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 15, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $247.1M in FY2025.
- Revenue grew 199% from FY2020 to FY2025.
- Gross margin of 71.6%, net margin 9.1%.
- Trading 57% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 43.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review INSULET CORP.
Write a review
News about INSULET CORP
News & sentiment via Polygon.io
